<DOC>
	<DOCNO>NCT00002102</DOCNO>
	<brief_summary>To provide trimetrexate glucuronate immunosuppressed patient Pneumocystis carinii pneumonia ( PCP ) investigational compound could provide significant medical benefit .</brief_summary>
	<brief_title>A Compassionate Treatment Protocol Use Trimetrexate Glucuronate With Leucovorin Protection Patients With Pneumocystis Carinii Pneumonia .</brief_title>
	<detailed_description>Patients receive intravenous infusion trimetrexate glucuronate leucovorin 21 day . Leucovorin continue 3 additional day discontinuation trimetrexate glucuronate .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Pneumocystis</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Trimetrexate</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Antiretroviral therapy ( discretion treat physician and/or medical monitor ) . Patients must : Presumptive definitive diagnosis Pneumocystis carinii pneumonia ( PCP ) . HIV positivity otherwise immunosuppressed . Demonstrated intolerance and/or resistance trimethoprim/sulfamethoxazole course therapy current episode candidate parenteral pentamidine , OR document history intolerance prior episode . Consent parent guardian le 18 year age . NOTE : In general , patient meet eligibility criterion U.S. Biosciencesponsored clinical trial trimetrexate would eligible Compassionate Use protocol . Exclusion Criteria Patients follow prior condition exclude : History Type I hypersensitivity ( i.e. , urticaria , angioedema , anaphylaxis ) , exfoliative dermatitis , lifethreatening reaction trimetrexate .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 1994</verification_date>
	<keyword>Trimetrexate</keyword>
	<keyword>Pneumonia , Pneumocystis carinii</keyword>
	<keyword>Leucovorin</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>